The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
The hemophilias--from royal genes to gene therapy
Abstract
Of the various types of hemophilia, the most common of these lifelong bleeding disorders are due to an inherited deficiency of factor VIII or factor IX (Table 1). The genes for these blood coagulation factors lie on the X chromosome, and when mutated, they cause the X-linked recessive traits hemophilia A and B. Since these disorders are X-linked, they usually occur in males. Usually, the affected boy has inherited the mutant gene (XH ) from his carrier mother (X H/X ), but about 30 percent of cases arise from a spontaneous mutation, and there is . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bleeding sequelae correlate with plasma FVIII/FIX activity (FVIII:C/FIX:C), such that spontaneous hemorrhage occurs in severe HA/HB (FVIII/FIX:C <1% of normal), less commonly in moderate HA/HB (FVIII/FIX:C 1%–5% of normal), and typically only following trauma in mild HA/HB (FVIII/FIX:C >5%–40% of normal).171”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [171]
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
A new variant of Creutzfeldt-Jakob disease in the UK
Will, R. G., Ironside, J. W., Zeidler, M., Estibeiro, K., Cousens, S. N., Smith, P. G., Alperovitch, A., Poser, S., Pocchiari, M., & Hofman, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91412-9 · Cited by 2,707
The Unusual Origin of the Polymerase Chain Reaction
Mullis, K. B. (1990) · Scientific American · doi:10.1038/scientificamerican0490-56 · Cited by 1,104
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Characterization of the human factor VIII gene
Gitschier, J., Wood, W. I., Goralka, T. M., Wion, K. L., Chen, E. Y., Eaton, D. H., Vehar, G. A., Capon, D. J., & Lawn, R. M. (1984) · Nature · doi:10.1038/312326a0 · Cited by 988
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
Lakich, D., Kazazian, H. H., Antonarakis, S. E., & Gitschier, J. (1993) · Nature Genetics · doi:10.1038/ng1193-236 · Cited by 788
Expression of active human factor VIII from recombinant DNA clones
Wood, W. I., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., et al. (1984) · Nature · doi:10.1038/312330a0 · Cited by 694
Self-citationIncidence of development of factor VIII and factor IX inhibitors in haemophiliacs
Ehrenforth, S., Kreuz, W., Linde, R., Funk, M., Güngor, T., Krackhardt, B., Kornhuber, B., & Scharrer, I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90874-3 · Cited by 605
Platelet activity of high‐dose factor VIIa is independent of tissue factor
Monroe, D. M., Hoffman, M., Oliver, J. A., & Roberts, H. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4463256.x · Cited by 534
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Research works printed but not linked: 8
- 10.1097/00043426-199901000-00022 · doi:10.1097/00043426-199901000-00022
- Bray GL, 1994, Blood, 83, 2428
- White G, 1998, Semin Hematol, 35, 33
- Abshire TC, 2000, Thromb Haemost, 38, 811
- Lusher JM, 2000, Blood, 96, 266a
- Ingerslev J, 1996, Haemostasis, 26, 118
- Domingo P, 1998, AIDS, 12, 529
- Soucie JM, 2000, Blood, 96, 437
Cited by
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, J., Oldenburg, J., Paz-Priel, I., Negrier, C., Niggli, M., Mancuso, M. E., Schmitt, C., Jiménez-Yuste, V., Kempton, C., Dhalluin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803550 · Cited by 763
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Bleeding sequelae correlate with plasma FVIII/FIX activity (FVIII:C/FIX:C), such that spontaneous hemorrhage occurs in severe HA/HB (FVIII/FIX:C <1% of normal), less commonly in moderate HA/HB (FVIII/FIX:C 1%–5% of normal), and typically only following trauma in mild HA/HB (FVIII/FIX:C >5%–40% of normal).(171) Thus, a…”
Background
Metadata
- Authors
- Mannucci, P. M., & Tuddenham, E. G. D.
- Affiliations
- University of Milan (IT)
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-06-07
- Volume
- 344
- Issue
- 23
- Pages
- 1773-1779
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2026502021
- Cited by
- 1,110
- References
- 66
- Citations by year
- 2026: 33 · 2025: 41 · 2024: 50 · 2023: 59 · 2022: 68 · 2021: 62 · 2020: 81 · 2019: 59 · 2018: 60 · 2017: 51 · 2016: 37 · 2015: 51 · 2014: 58 · 2013: 65 · 2012: 45
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- hemophilia, hemophilia A, hemophilia B, X-linked recessive inheritance, gene therapy, coagulation factors, spontaneous mutation
- MeSH terms
- Factor IX, Factor VIII, Hemophilia A, Humans, Mutation, Protein Conformation, Recombinant Proteins, Virus Diseases, Genetic Therapy, Disease Transmission, Infectious
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The hemophilias--from royal genes to gene therapy. https://app.cochat.ai/papers/10.1056/nejm200106073442307
- The paper
- Mannucci, P. M., & Tuddenham, E. G. D. (2001). The hemophilias--from royal genes to gene therapy. New England Journal of Medicine. https://doi.org/10.1056/nejm200106073442307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.